# Federal Register #DEA-1792

DEA notices applications to manufacture Schedule I substances and import fentanyl

**Posted:** November 02, 2026
**Respond By:** December 02, 2026
**Identifier:** DEA-1792

The Department of Justice published Drug Enforcement Administration notices concerning controlled-substance manufacturing and import applications.
- **Government buyer:** U.S. Department of Justice (DOJ), Drug Enforcement Administration (DEA); the attached notice also references the Bureau of Prisons (BOP).
- **Named companies:** **AJNA Biosciences** applied to bulk manufacture three Schedule I substances for a new FDA-regulated drug program. **Globyz Pharma LLC** applied to import Schedule II fentanyl in dosage form for analytical testing and development.
- **Substances and drug codes:**
  - Marihuana Extract — 7350, Schedule I.
  - Marihuana — 7360, Schedule I.
  - Tetrahydrocannabinols — 7370, Schedule I.
  - Fentanyl — 9801, Schedule II.
- AJNA Biosciences’ proposed purposes include research, clinical trials, analytical work, and customer sales. Globyz Pharma LLC’s application is limited to fentanyl imports for analytical testing and development; it does not propose importing finished dosage forms for commercial sale.
- No quantities, commercial purchase, or service line items are specified. These notices concern applications for controlled-substance activities, not a conventional product procurement.

### Description

Globyz Pharma LLC applied to register as an importer of fentanyl, a Schedule II controlled substance (drug code 9801). The company plans to import the substance in dosage form for analytical testing and development; no other activity for this drug code is authorized under the proposed registration. Eligible parties may submit electronic comments or objections, or request a hearing, by December 2, 2026.

[View original listing](https://www.federalregister.gov/documents/2026/11/02/2026-22288/importer-of-controlled-substances-application-globyz-pharma-llc)